[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-363306-en":59,"doc-seo-363306-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},363306,2336477405376,"Stanley","https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Radiotherapy combined with immunotherapy for esophageal cancer: current status and challenge","With the advent of the immunotherapy era, combining radiotherapy and immunotherapy has become a key strategy to improve outcomes in esophageal cancer. Beyond direct cytotoxicity, radiotherapy reshapes anti-tumor immunity by modulating immune responses in the tumor and surrounding microenvironment. This review summarizes radiation-driven immunomodulatory mechanisms, assesses clinical efficacy and safety of combination approaches, and highlights present applications, limitations, and future directions. Prospective trials are needed to optimize timing, combinations, and biomarkers.","Journal of Cancer Research and Clinical Oncology (2026) 152:103  \n[https://doi.org/10.1007/s00432-026-06480-2](https://doi.org/10.1007/s00432-026-06480-2)  \nREVIEW  \nRadiotherapy combined with immunotherapy for esophageal cancer: current status and challenge  \nYuqing Wang1,2 · Junjie Gu1 · Xinchen Sun1,2  \nReceived: 6 January 2026 / Accepted: 4 April 2026 © The Author(s) 2026  \nAbstract  \nWith the advent of the immunotherapy era, the combination of radiotherapy and immunotherapy has become a critical strategy to enhance patient outcomes. In addition to its direct cytotoxicity, radiotherapy modulates the immune response within the tumor and its surrounding microenvironment by stimulating the body’s anti-tumor immune response. This interplay provides the rationale for combining radiotherapy with immunotherapy. This review will summarize the immunomodulatory mechanisms of radiation therapy, evaluate the clinical efficacy and safety of combining radiotherapy with immunotherapy, and outline its current applications, challenges, and future potential. In the future, the combination of radiotherapy and immunotherapy holds immense potential in esophageal cancer treatment. Through additional prospective clinical trials exploring optimal combinations, timing, and biomarkers, we can further refine treatment strategies and enhance patient survival.  \nKeywords Esophageal cancer · Radiotherapy · Immunotherapy · Immunomodulation  \nIntroduction  \nAccording to 2022 global cancer statistics, esophageal cancer (EC) ranked as the seventh leading cause of cancerrelated deaths (Bray et al. 2024) . Due to its high incidence rate, treatment difficulties, and generally poor outcomes, EC has become a major global public health challenge. Surgery is the standard treatment for early EC. However, since EC lacks evident clinical symptoms in early stages, most patients are not diagnosed early enough to receive timely surgical treatment.  \nRadiotherapy (RT) is a primary modality for locally definitive treatment, and also plays an important role in the comprehensive treatment of locally advanced and advanced EC. The basis of RT is to directly kill tumor cells. In recent  \nYuqing Wang and Junjie Gu have contributed equally to this work.  \n􀀍 Xinchen Sun [sunxinchen@njmu.edu.cn](sunxinchen@njmu.edu.cn)  \n1 Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China  \n2 The First School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China  \nyears, it has been found that RT can also modulate the tumor immune microenvironment through complex mechanismsand induce an anti-tumor immune response. Notably, the effect of RT on the tumor immune microenvironment is a double-edged sword (Berzaghi et al. 2019; McLaughlin et al. 2020): it can stimulate or suppress the tumor immune microenvironment, and the final effect depends on many factors, such as pre-existing immune context, dose and fractionation regimen.  \nWith the rapid advancement of cancer immunotherapy, immune checkpoint inhibitors (ICIs) have shown potential in the treatment of cancer by opening up new possibilities in the comprehensive treatment of malignant tumors (Kwantwi 2023) . Although ICIs are changing the cancer treatment landscape, only a few patients currently benefit from them. In this case, the combination of radiotherapy and immunotherapy has broad prospects. It has been found that RT can improve the effectiveness of ICIs by upregulating the expression of PD-L1 (Programmed Cell Death Ligand 1) in the tumor microenvironment (TME), and ICIs may magnify the biological effects of RT (Li et al. 2025b) . The possible synergistic mechanism provides a rational basis for the combination therapy.  \nRecently, neoadjuvant immunochemoradiotherapy (nICRT) has shown potential as a new treatment modality  \n1 3  \nforresectable EC. With the deep understanding ofthe immunomodulatory effects of RT, the research on RT combination therapies has ","cbCaioFNUMXPa67x","https://ap.wps.com/l/cbCaioFNUMXPa67x","pdf",1674403,15,"English","en",105,"# Abstract\n# Introduction\n## Radiotherapy and immune modulation\n## Role of immune checkpoint inhibitors\n# RT immunomodulation\n## The Impact of RT on the TME","[{\"question\":\"Why does combining radiotherapy with immunotherapy improve esophageal cancer treatment?\",\"answer\":\"Radiotherapy not only kills tumor cells but also modulates the immune response in the tumor microenvironment, supporting an anti-tumor immune effect. The review frames this interaction as the rationale for combination therapy.\"},{\"question\":\"How does radiotherapy influence the tumor immune microenvironment?\",\"answer\":\"Radiotherapy can have a dual effect on the tumor immune microenvironment, either stimulating or suppressing immune activity depending on factors such as pre-existing immune context and the dose/fractionation regimen.\"},{\"question\":\"What are the main challenges and future directions for this combination?\",\"answer\":\"The review emphasizes ongoing challenges and the need for additional prospective clinical trials to refine optimal combinations, timing, and biomarkers to improve survival outcomes.\"}]","Radiotherapy combined with immunotherapy for esophageal cancer: current status and challenge | PDF",1790150716,38,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a94ab99092d211c9322d24ae1e1fe78.webp",983,1305,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbeb363b83b3b165c75883ef524fe2de.webp",982,1304,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8385873dbc78981bd7f881b467507e0.webp",981,1303,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/539fb7c1ca7d43728af11324230d94f0.webp",980,1301,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"radiotherapy-combined-with-immunotherapy-for-esophageal-cancer-current-status-and-challenge","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/radiotherapy-combined-with-immunotherapy-for-esophageal-cancer-current-status-and-challenge/363306/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/radiotherapy-combined-with-immunotherapy-for-esophageal-cancer-current-status-and-challenge/363306.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-11-09","2026-09-23",true,{"@type":136,"interactionType":137,"userInteractionCount":29},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"Why does combining radiotherapy with immunotherapy improve esophageal cancer treatment?","Question",{"text":146,"@type":147},"Radiotherapy not only kills tumor cells but also modulates the immune response in the tumor microenvironment, supporting an anti-tumor immune effect. The review frames this interaction as the rationale for combination therapy.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"How does radiotherapy influence the tumor immune microenvironment?",{"text":151,"@type":147},"Radiotherapy can have a dual effect on the tumor immune microenvironment, either stimulating or suppressing immune activity depending on factors such as pre-existing immune context and the dose/fractionation regimen.",{"name":153,"@type":144,"acceptedAnswer":154},"What are the main challenges and future directions for this combination?",{"text":155,"@type":147},"The review emphasizes ongoing challenges and the need for additional prospective clinical trials to refine optimal combinations, timing, and biomarkers to improve survival outcomes.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790729412]